Hematology News

Two hematologists-oncologists have assumed key leadership roles at Atlantic Hematology Oncology, part of Atlantic Health System Cancer Care.

Rivaroxaban led to substantially lower incidence of venous thromboembolism and death of VTE among ambulatory patients with cancer death during the treatment intervention, according to results of the phase 3b randomized trial CASSINI published in The New England Journal of Medicine.

Researchers at Emory University and Georgia Institute of Technology have developed a smartphone app designed to detect anemia.

The investigational gene therapy AMT-061 showed increases in factor IX activity sustained at 25% to 51% of normal among patients with severe or moderately severe hemophilia B, according to updated clinical data reported by the manufacturer.

Andexanet alfa reversed the anticoagulation effects of factor Xa inhibitors in most patients with acute major bleeding caused by a factor Xa inhibitor, according to the full data from the ANNEXA-4 study presented at the International Stroke Conference.

The FDA today approved caplacizumab-yhdp injection as the first therapy specifically indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura, a rare and life-threatening blood clotting disorder.

The FDA granted orphan drug designation to the C3 complement inhibitor APL-2 for the treatment of autoimmune hemolytic anemia.

Immersive virtual reality appeared effective as a complementary therapy to manage vasoocclusive pain among patients with sickle cell disease.

Fecal immunochemical tests have lower positive predictive value of colorectal cancer among patients who are regular users of aspirin and direct-acting oral anticoagulants, according to research published in Gastroenterology.

Roy L. Silverstein, MD, has started his year-long term as president of ASH.